{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:25:29Z","timestamp":1777472729964,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1130043"],"award-info":[{"award-number":["1130043"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["POIG.02.01.00-12-167\/08"],"award-info":[{"award-number":["POIG.02.01.00-12-167\/08"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bbrc.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T21:44:34Z","timestamp":1528235074000},"page":"209-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u03b11-and \u03b2-adrenergic antagonist labetalol induces morphological changes in human erythrocytes"],"prefix":"10.1016","volume":"503","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5499-6091","authenticated-orcid":false,"given":"Pablo","family":"Zambrano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-978X","authenticated-orcid":false,"given":"Mario","family":"Suwalsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Jemiola-Rzeminska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimierz","family":"Strzalka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2018.06.004_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004872-200401000-00003","article-title":"Worldwide prevalence of hypertension: a systematic review","volume":"22","author":"Kearney","year":"2004","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.bbrc.2018.06.004_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.HYP.0000142248.54761.56","article-title":"The burden of adult hypertension in the United States 1999 to 2000: a rising tide","volume":"44","author":"Fields","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.bbrc.2018.06.004_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(14)61468-9","article-title":"Hypertension","volume":"386","author":"Poulter","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2018.06.004_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/S1516-31802010000100011","article-title":"First-line drugs for hypertension","volume":"128","author":"Wright","year":"2010","journal-title":"Sao Paulo Med. J."},{"key":"10.1016\/j.bbrc.2018.06.004_bib5","doi-asserted-by":"crossref","first-page":"211S","DOI":"10.1111\/j.1365-2125.1979.tb04783.x","article-title":"Use of labetalol in the treatment of severe hypertension during pregnancy","volume":"8","author":"Michael","year":"1979","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.06.004_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pcad.2016.10.005","article-title":"Beta-adrenergic receptor blockers in hypertension: alive and well","volume":"59","author":"Frishman","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.bbrc.2018.06.004_bib7","first-page":"704","article-title":"Labetalol","volume":"17","author":"Carter","year":"1983","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.bbrc.2018.06.004_bib8","series-title":"xPharmCompr. Pharmacol. Ref","first-page":"1","article-title":"Labetalol","author":"Gruetter","year":"2007"},{"key":"10.1016\/j.bbrc.2018.06.004_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3949\/ccjm.61.1.59","article-title":"Labetalol and other agents that block both alpha- and beta-adrenergic receptors","volume":"61","author":"Pearce","year":"1994","journal-title":"Cleve. Clin. J. Med. Off."},{"key":"10.1016\/j.bbrc.2018.06.004_bib10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00404-012-2371-x","article-title":"Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy","volume":"286","author":"Giannubilo","year":"2012","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.bbrc.2018.06.004_bib11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1476-5381.1991.tb12513.x","article-title":"The\u03b1and\u03b2adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers","volume":"104","author":"Riva","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.06.004_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/j.1875-9114.1983.tb03252.x","article-title":"Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects","volume":"3","author":"MacCarthy","year":"1983","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbrc.2018.06.004_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-113-3-210","article-title":"Labetalol hepatotoxicity","volume":"113","author":"Clark","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bbrc.2018.06.004_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-9343(89)80706-5","article-title":"Fatal labetalol-induced hepatic injury","volume":"87","author":"Douglas","year":"1989","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbrc.2018.06.004_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0009-3084(94)90177-5","article-title":"Maintenance and consequences of membrane phospholipid asymmetry","volume":"73","author":"Devaux","year":"1994","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.bbrc.2018.06.004_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/med.10009","article-title":"Chemical control of phospholipid distribution across bilayer membranes","volume":"22","author":"Middleton Boon","year":"2002","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbrc.2018.06.004_bib17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.bbrc.2016.12.111","article-title":"Invitro effects of the anti-Alzheimer drug memantine on the human erythrocyte membrane and molecular models","volume":"483","author":"Zambrano","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2018.06.004_bib18","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.bbamem.2015.08.017","article-title":"An in\u00a0vitro study on the antioxidant capacity of usnic acid on human erythrocytes and molecular models of its membrane","volume":"1848","author":"Suwalsky","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2018.06.004_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-4157(98)00006-9","article-title":"Phases and phase transitions of the phosphatidylcholines","volume":"1376","author":"Koynova","year":"1998","journal-title":"Biochim. Biophys. Acta Rev. Biomembr."},{"key":"10.1016\/j.bbrc.2018.06.004_bib20","series-title":"Polymeric Materials Encyclopedia, Twelve Volume Set","author":"Salamone","year":"1996"},{"key":"10.1016\/j.bbrc.2018.06.004_bib21","doi-asserted-by":"crossref","first-page":"30902","DOI":"10.1103\/PhysRevE.63.030902","article-title":"Anomalous swelling in phospholipid bilayers is not coupled to the formation of a ripple phase","volume":"63","author":"Mason","year":"2001","journal-title":"Phys. Rev. E"},{"key":"10.1016\/j.bbrc.2018.06.004_bib22","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1103\/PhysRevE.61.5668","article-title":"Clarification of the ripple phase of lecithin bilayers using fully hydrated, aligned samples","volume":"61","author":"Katsaras","year":"2000","journal-title":"Phys. Rev. E: Stat. Phys., Plasmas, Fluids, Relat. Interdiscip. Top."},{"key":"10.1016\/j.bbrc.2018.06.004_bib23","first-page":"353","article-title":"Lipid intermolecular hydrogenbonding: influence on structural organization and membrane function","volume":"906","author":"Boggs","year":"1987","journal-title":"BBA - Reviews on Biomembr"},{"key":"10.1016\/j.bbrc.2018.06.004_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-4157(00)00016-2","article-title":"Structure of lipid bilayers","volume":"1469","author":"Nagle","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2018.06.004_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1535-5535-04-00243-6","article-title":"High throughput measurement of drug pKa values for ADME screening","volume":"8","author":"Comer","year":"2003","journal-title":"J.\u00a0Assoc. Lab. Autom."},{"key":"10.1016\/j.bbrc.2018.06.004_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0009-3084(01)00207-9","article-title":"The influence of structure and redox state of prenylquinones on thermotropic phase behaviour of phospholipids in model membranes","volume":"114","author":"Jemio\u0142a-Rzemi\u0144ska","year":"2002","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.bbrc.2018.06.004_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.colsurfb.2010.03.017","article-title":"Microcalorimetric and zeta potential study on binding of drugs on liposomes","volume":"78","author":"Ikonen","year":"2010","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"10.1016\/j.bbrc.2018.06.004_bib28","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1073\/pnas.71.11.4457","article-title":"Biological membranes as bilayer couples. A molecular mechanism of drug-erythrocyte interactions","volume":"71","author":"Sheetz","year":"1974","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.bbrc.2018.06.004_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3109\/10641968009037147","article-title":"Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension","volume":"2","author":"Lamming","year":"1980","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.bbrc.2018.06.004_bib30","first-page":"681","article-title":"A\u00a0review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug","volume":"3","author":"Brittain","year":"1976","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Pt 3","key":"10.1016\/j.bbrc.2018.06.004_bib31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1469-7793.1999.0781u.x","article-title":"Beta-adrenergic agonists regulate cell membrane fluctuations of human erythrocytes","volume":"516","author":"Tuvia","year":"1999","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.bbrc.2018.06.004_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-2952(82)90243-X","article-title":"Receptor binding sites for beta-adrenergic ligands on human erythrocytes","volume":"31","author":"Sager","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.06.004_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00562897","article-title":"Relationship between plasma concentrations and pharmacological effects of labetalol","volume":"11","author":"Richards","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1831310X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1831310X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:32:37Z","timestamp":1762093957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X1831310X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0006291X1831310X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.06.004","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b11-and \u03b2-adrenergic antagonist labetalol induces morphological changes in human erythrocytes","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}